Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Study of Zonisamide Sustained Release (SR) 360 mg Versus Placebo in the Prevention of Weight Gain Associated With Olanzapine Therapy for Psychosis

NCT00734435 is registered in ClinicalTrials.gov with Orexigen Therapeutics, Inc as lead sponsor.

NCT NCT00734435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00734435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Study of Zonisamide Sustained Release (SR) 360 mg Versus Placebo in the Prevention of Weight Gain Associated With Olanzapine Therapy for Psychosis
Lead sponsor
Orexigen Therapeutics, Inc
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2008
Completion date
December 31, 2008
Enrollment
26 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia, schizophreniform disorder